<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387737</url>
  </required_header>
  <id_info>
    <org_study_id>TA-7284-06</org_study_id>
    <nct_id>NCT01387737</nct_id>
  </id_info>
  <brief_title>Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or
      combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type
      2 diabetes mellitus on 52 weeks oral administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 2-arm, parallel group, open-label study to evaluate the safety and
      efficacy of TA-7284 in Japanese patients with Type 2 diabetes mellitus, who are not optimally
      controlled on diet and exercise or with oral anti-hyperglycaemic agent. The patients will
      receive either TA-7284-Low or TA-7284-High orally alone or in combination with oral
      anit-hyperglycaemic agent for 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events</measure>
    <time_frame>54 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1299</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TA-7284-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TA-7284-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-7284-Low</intervention_name>
    <description>TA-7284-Low</description>
    <arm_group_label>TA-7284-Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TA-7284-High</intervention_name>
    <description>TA-7284-High</description>
    <arm_group_label>TA-7284-High</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age ≥20 years old

          -  Diagnosed with Type 2 diabetes mellitus at least 3 months before screening

          -  HbA1c of ≥7.0% and ≤10.0% (monotherapy group)

          -  HbA1c of ≥7.0% and ≤10.5% (combination therapy group)

        Exclusion Criteria:

          -  Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder,
             secondary diabetes mellitus

          -  Past or current history of severe diabetic complications

          -  Fasting plasma glucose &gt; 270 mg/dL before treatment start

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria

          -  Patients requiring insulin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuya Inagaki, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuoki Kondo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <results_first_submitted>March 26, 2014</results_first_submitted>
  <results_first_submitted_qc>March 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2014</results_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TA-7284</keyword>
  <keyword>JNJ-28431754</keyword>
  <keyword>Canagliflozin</keyword>
  <keyword>Sodium Glucose Co-Transporter (SGLT2 inhibitor)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TA-7284-Low</title>
          <description>TA-7284 low dose, once daily for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>TA-7284-High</title>
          <description>TA-7284 high dose, once daily for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="584"/>
                <participants group_id="P2" count="715"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="532"/>
                <participants group_id="P2" count="641"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clearly not eligible for the study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TA-7284-Low</title>
          <description>TA-7284 low dose, once daily for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>TA-7284-High</title>
          <description>TA-7284 high dose, once daily for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="584"/>
            <count group_id="B2" value="715"/>
            <count group_id="B3" value="1299"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="436"/>
                    <measurement group_id="B2" value="520"/>
                    <measurement group_id="B3" value="956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="503"/>
                    <measurement group_id="B3" value="924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events</title>
        <time_frame>54 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TA-7284-Low</title>
            <description>TA-7284 low dose, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>TA-7284-High</title>
            <description>TA-7284 high dose, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events</title>
          <units>percentage of incidences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="715"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c</title>
        <time_frame>Week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose</title>
        <time_frame>Week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <time_frame>Week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure</title>
        <time_frame>Week 52</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 52</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TA-7284-Low</title>
          <description>TA-7284 low dose, once daily for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>TA-7284-High</title>
          <description>TA-7284 high dose, once daily for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis subacute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15">Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15">Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Vocal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Suture removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="371" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="464" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15">Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood ketone body increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia unawareness</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

